1. 1141PDAssociation between immune-related adverse events and efficacy in patients treated with anti-PD-(L)1. (23rd October 2018) Authors: Kfoury, M; Voisin, A-L; Najean, M; Champiat, S; Laghouati, S; Michot, J-M; Robert, C; Mateus, C; Albiges, L; Besse, B; Massard, C; Texier, M; Lambotte, O; Marabelle, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 182TiPEXPRESS study: A multicenter, prospective trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors. (23rd October 2018) Authors: Italiano, A; Le Saux, O; André, F; Filleron, T; Spaeth, D; Heudel, P-E; Albiges, L; Bachelot, T; Gonçalves, A; Pierga, J-Y; Barlesi, F; Boige, V; Lebbe, C; Mortier, L; Frenel, J-S; Tredan, O; Jimenez, M; Legrand, F; Ferté, C Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 49P Thromboembolic risk assessment in patients receiving combination of anti-angiogenic plus anti-PD1 or anti-PD-L1: A descriptive study. (15th December 2019) Authors: Bravo, P; Vss, B; Baldini, C; Romano, P Martin; Hollebecque, A; Varga, A; Vuagnat, P; Champiat, S; Marabelle, A; Escudier, B; Albiges, L; Loriot, Y; Massard, C; Cataldi, A; Babai, S; Voisin, A-L; Lambotte, O; Annereau, M; Michot, J-M Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 868PDBrain metastases response to nivolumab in patients with renal cell carcinoma (RCC): Prospective analysis from the GETUG-AFU 26 (NIVOREN) trial. (23rd October 2018) Authors: Flippot, R; Dalban, C; Laguerre, B; Borchiellini, D; Gravis, G; Negrier, S; Chevreau, C M; Joly, F; Geoffrois, L; Ladoire, S; Mahammedi, H; Tantot, F; Escudier, B; Albiges, L Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 870PDEfficacy and safety of axitinib in metastatic papillary renal carcinoma (mPRC): Results of a GETUG multicenter phase II trial (Axipap). (23rd October 2018) Authors: Negrier, S; Rioux-Leclercq, N; Ravaud, A; Gravis, G; Geoffrois, L; Chevreau, C M; Rolland, F; Blanc, E; Segura-Ferlay, C; Perol, D; Gross Goupil, M; Dermeche, S; Flechon, A; Albiges, L; Escudier, B Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 878PTiNivo - tivozanib combined with nivolumab: Safety and efficacy in patients with metastatic renal cell carcinoma (mRCC). (23rd October 2018) Authors: Barthelemy, P; Escudier, B; Ravaud, A; Negrier, S; Needle, M N; Albiges, L Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. (30th March 2018) Authors: Derosa, L; Hellmann, M D; Spaziano, M; Halpenny, D; Fidelle, M; Rizvi, H; Long, N; Plodkowski, A J; Arbour, K C; Chaft, J E; Rouche, J A; Zitvogel, L; Zalcman, G; Albiges, L; Escudier, B; Routy, B Journal: Annals of oncology Issue: Volume 29:Number 6(2018) Page Start: 1437 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗